Company registration number 08898793 (England and Wales)
UK ONCOLOGY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 AUGUST 2024
PAGES FOR FILING WITH REGISTRAR
UK ONCOLOGY LIMITED
COMPANY INFORMATION
- 1 -
Director
Dr Gregory Wilson
Company number
08898793
Registered office
8 Darley Avenue
West Didsbury
Manchester
UK
M20 2XF
Accountants
Xeinadin
Riverside House
Kings Reach Business Park
Yew Street
Stockport
Cheshire
SK4 2HD
UK ONCOLOGY LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 10
UK ONCOLOGY LIMITED
BALANCE SHEET
AS AT
28 AUGUST 2024
28 August 2024
- 2 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
5
-
0
750
Tangible assets
6
32,006
40,951
Investment property
7
503,000
508,500
535,006
550,201
Current assets
Debtors
8
41,969
27,514
Investments
9
1,785,706
963,017
Cash at bank and in hand
1,109,554
1,532,574
2,937,229
2,523,105
Creditors: amounts falling due within one year
10
(35,462)
(17,729)
Net current assets
2,901,767
2,505,376
Total assets less current liabilities
3,436,773
3,055,577
Provisions for liabilities
(132,332)
(45,832)
Net assets
3,304,441
3,009,745
Capital and reserves
Called up share capital
12
100
100
Revaluation reserve
11
372,993
162,222
Profit and loss reserves
2,931,348
2,847,423
Total equity
3,304,441
3,009,745
UK ONCOLOGY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
28 AUGUST 2024
28 August 2024
- 3 -

For the financial year ended 28 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 28 May 2025
Dr Gregory Wilson
Director
Company registration number 08898793 (England and Wales)
UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 AUGUST 2024
- 4 -
1
Accounting policies
Company information

UK Oncology Limited is a private company limited by shares incorporated in England and Wales. The registered office is 8 Darley Avenue, West Didsbury, Manchester, UK, M20 2XF.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of investment properties and other investments at fair value. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements , the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.true

1.3
Turnover

Turnover comprises the fair value of the consideration received or receivable for provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

 

The company recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity;

and specific criteria have been met for each of the company's activities.

 

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of an entity represents the excess of the cost of acquisition over the company's interest in the net fair value of identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computer equipment
33% Reducing balance
Motor vehicles
25% Reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 AUGUST 2024
1
Accounting policies
(Continued)
- 5 -
1.6
Investment properties

Investment property comprises of property and interests in land held either to earn rental income or for capital appreciation, or both. Investment properties are initially measured at cost, including related transaction costs. Borrowing costs associated with direct expenditure on investment properties under development are capitalised. Interest is capitalised as from the commencement of the development work until the date of practical completion or, if earlier, the date that outgoings exceeded income. After initial recognition, investment properties are carried at their fair values based on market value as determined at each reporting date. The difference between the fair value of investment property at the reporting date and it's carrying amount prior to re-measurement is included in the income statement as valuation surplus or deficit. Profit on disposal is determined as the difference between the sales proceeds and the carrying amount of the asset at the commencement of the accounting period plus capital expenditure in the period.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 AUGUST 2024
1
Accounting policies
(Continued)
- 6 -
1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 AUGUST 2024
- 7 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Revaluation of investment property

Investment property is carried at fair value, with changes in fair value being recognised in the statement of income and retained earnings. The valuation of investment property is inherently subjective due to, among other factors, the individual nature of the property, its location and the expected future rental revenues from that particular property. As a result, the valuation the company places on its property portfolio is subject to a degree of uncertainty and are made on the basis of assumptions which may not prove to be accurate, particularly in period of volatility or low transaction flow in the property market.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
2
2
4
Operating profit
2024
2023
Operating profit for the year is stated after charging:
£
£
Depreciation of owned tangible fixed assets
11,132
14,241
UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 AUGUST 2024
- 8 -
5
Intangible fixed assets
Goodwill
£
Cost
At 29 August 2023 and 28 August 2024
15,000
Amortisation and impairment
At 29 August 2023
14,250
Amortisation charged for the year
750
At 28 August 2024
15,000
Carrying amount
At 28 August 2024
-
0
At 28 August 2023
750
6
Tangible fixed assets
Computer equipment
Motor vehicles
Total
£
£
£
Cost
At 29 August 2023
16,038
63,879
79,917
Additions
2,187
-
0
2,187
At 28 August 2024
18,225
63,879
82,104
Depreciation and impairment
At 29 August 2023
11,681
27,285
38,966
Depreciation charged in the year
1,984
9,148
11,132
At 28 August 2024
13,665
36,433
50,098
Carrying amount
At 28 August 2024
4,560
27,446
32,006
At 28 August 2023
4,357
36,594
40,951
7
Investment property
2024
£
Fair value
At 29 August 2023
508,500
Revaluations
(5,500)
At 28 August 2024
503,000
UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 AUGUST 2024
7
Investment property
(Continued)
- 9 -

Investment properties are properties held to earn rentals and/or for capital appreciation. Investment properties are initially measured at cost, including transaction costs.

 

Subsequently investment properties are measured at fair value. Investment property valuations are based on an open market value. Deferred tax is provided on these movements. Gains and losses arising from changes in the fair value of investment properties are included within the statement of income and retained earnings in the period in which they arise.

 

There has been no valuation of investment properties by an independent valuer.

8
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
35,264
20,373
Other debtors
6,705
7,141
41,969
27,514
9
Current asset investments
2024
2023
£
£
Other investments
1,785,706
963,017

Investments with a net book value of £1,649,550 (2023: £826,861) are listed on a recognised stock exchange and had a market value of £1,649,550 (2023: £826,861) at the financial year end.

10
Creditors: amounts falling due within one year
2024
2023
£
£
Taxation and social security
22,712
1,764
Other creditors
12,750
15,965
35,462
17,729
11
Revaluation reserve
2024
2023
£
£
At the beginning of the year
162,222
45,799
Revaluation surplus arising in the year
(5,500)
5,000
Deferred tax on revaluation of tangible assets
(86,279)
(27,309)
Other movements
302,550
138,732
At the end of the year
372,993
162,222
UK ONCOLOGY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 AUGUST 2024
- 10 -
12
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
13
Related party transactions

During the year the director advanced monies to the company on an interest free basis, the amount owing to the director at the year end date was £312 (2023: £1,311). This amount is interest free and repayable on demand.

14
Control

The company is controlled by the Director by virtue of his 100% shareholding.

2024-08-282023-08-29falsefalsefalse28 May 2025CCH SoftwareCCH Accounts Production 2025.100No description of principal activityDr Gregory Wilson088987932023-08-292024-08-2808898793bus:Director12023-08-292024-08-2808898793bus:RegisteredOffice2023-08-292024-08-28088987932024-08-28088987932023-08-2808898793core:NetGoodwill2024-08-2808898793core:NetGoodwill2023-08-2808898793core:ComputerEquipment2024-08-2808898793core:MotorVehicles2024-08-2808898793core:ComputerEquipment2023-08-2808898793core:MotorVehicles2023-08-2808898793core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-2808898793core:CurrentFinancialInstrumentscore:WithinOneYear2023-08-2808898793core:ShareCapital2024-08-2808898793core:ShareCapital2023-08-2808898793core:RevaluationReserve2024-08-2808898793core:RevaluationReserve2023-08-2808898793core:RetainedEarningsAccumulatedLosses2024-08-2808898793core:RetainedEarningsAccumulatedLosses2023-08-2808898793core:RevaluationReserve2023-08-2808898793core:RevaluationReserve2022-08-2808898793core:ShareCapitalOrdinaryShareClass12024-08-2808898793core:ShareCapitalOrdinaryShareClass12023-08-2808898793core:Goodwill2023-08-292024-08-2808898793core:ComputerEquipment2023-08-292024-08-2808898793core:MotorVehicles2023-08-292024-08-28088987932022-08-292023-08-2808898793core:NetGoodwill2023-08-2808898793core:NetGoodwill2023-08-292024-08-2808898793core:ComputerEquipment2023-08-2808898793core:MotorVehicles2023-08-28088987932023-08-2808898793core:CurrentFinancialInstruments2024-08-2808898793core:CurrentFinancialInstruments2023-08-2808898793core:WithinOneYear2024-08-2808898793core:WithinOneYear2023-08-2808898793core:RevaluationReserve2023-08-292024-08-2808898793bus:OrdinaryShareClass12023-08-292024-08-2808898793bus:OrdinaryShareClass12024-08-2808898793bus:OrdinaryShareClass12023-08-2808898793bus:PrivateLimitedCompanyLtd2023-08-292024-08-2808898793bus:SmallCompaniesRegimeForAccounts2023-08-292024-08-2808898793bus:FRS1022023-08-292024-08-2808898793bus:AuditExemptWithAccountantsReport2023-08-292024-08-2808898793bus:FullAccounts2023-08-292024-08-28xbrli:purexbrli:sharesiso4217:GBP